| Literature DB >> 24462981 |
Gertjan Lugthart1, Monique M van Ostaijen-Ten Dam2, Cornelia M Jol-van der Zijde2, Tessa C van Holten2, Michel G D Kester3, Mirjam H M Heemskerk3, Robbert G M Bredius4, Maarten J D van Tol2, Arjan C Lankester4.
Abstract
Human cytomegalovirus (CMV) reactivation frequently occurs during the early phase of immune recovery after allogeneic hematopoietic stem cell transplantation (HSCT). Whereas the recovery of virus-specific immunity in the early phase after HSCT is extensively studied, the impact of CMV on the reconstitution and composition of the T cell compartment long-term after HSCT is unknown. We analyzed T cell reconstitution 1 to 2 years after HSCT in 131 pediatric patients. One year after HSCT, patients with early CMV reactivation (n = 46) had 3-fold higher CD8(+) T cell numbers (median, 1323 versus 424 cells/μL; P < .0001) compared with patients without CMV reactivation (n = 85). This effect, caused by a major expansion of CD8(+) effector memory (EM) and end-stage effector (EMRA) T cells, was independent of pretransplantation donor and recipient CMV serostatus and not seen after Epstein-Barr virus or adenovirus reactivations. At 1 and 2 years after HSCT, the absolute numbers of CD8(+) naive and central memory T cells, as well as CD4(+) naive, CM, EM, and EMRA T cells, did not differ between patients with or without CMV reactivation. In the second year after HSCT, a significant contraction of the initially expanded CD8(+) EM and EMRA T cell compartments was observed in patients with early CMV reactivation. In conclusion, CMV reactivation early after pediatric HSCT leaves a specific and dynamic imprint on the size and composition of the CD8(+) T cell compartment without compromising the reconstitution of CD8(+) and CD4(+) naive and central memory T cells pivotal in the response to neo and recall antigens.Entities:
Keywords: Cytomegalovirus; Immune reconstitution; Pediatric hematopoietic stem cell transplantation; T cell differentiation
Mesh:
Year: 2014 PMID: 24462981 DOI: 10.1016/j.bbmt.2014.01.018
Source DB: PubMed Journal: Biol Blood Marrow Transplant ISSN: 1083-8791 Impact factor: 5.742